Musk threatens Apple with legal action over App Store bias towards OpenAI
Philadelphia—Brent Pfeiffenberger, the President and CEO of Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 34,712 shares of the company’s common stock. The shares were sold at an average price of $0.783 each, totaling approximately $27,179. The micro-cap biotech company, currently valued at $64.2 million, has seen its shares decline about 25% year-to-date, though InvestingPro analysis suggests the stock is undervalued at current levels.
This transaction was executed on February 18, 2025, and was primarily to cover tax withholding obligations tied to the vesting of restricted stock units. Following the sale, Pfeiffenberger retains ownership of 1,192,545 shares. Despite the company’s current weak financial health score, analysts maintain price targets ranging from $4 to $13, significantly above the current trading price of $0.75.
The sale was automatic and not at the discretion of Pfeiffenberger, as noted in the filing. Get deeper insights into Century Therapeutics’ financial health metrics and exclusive analysis with InvestingPro.
In other recent news, Century Therapeutics has announced a partnership with Friedrich-Alexander University Erlangen-Nürnberg to conduct a Phase 1/2 trial of its cell therapy CNTY-101 for B-cell mediated autoimmune diseases. This trial, named CARAMEL, will evaluate the therapy’s safety and efficacy, with a start date set for mid-2025 pending regulatory approval. Additionally, Century Therapeutics has reported promising data from its Phase I ELiPSE-1 study, showing an 83% overall response rate in B cell lymphoma patients, with no severe adverse events reported. However, the company faced a setback as Bristol-Myers Squibb (NYSE:BMY) decided to end their collaboration on developing therapies for acute myeloid leukemia and multiple myeloma, effective March 2025. Despite this, Century Therapeutics maintains a strong cash position of $245 million as of the third quarter of 2024.
Analysts have weighed in on these developments, with Piper Sandler maintaining an Overweight rating on Century shares while adjusting its price target to $4, reflecting recent corporate updates. Clear Street has initiated coverage with a Buy rating and a $9 price target, citing the potential of Century’s iPSC platform and technology. The firm sees favorable market conditions for Century Therapeutics, emphasizing the company’s ability to impact significant markets like B-cell malignancies and autoimmune diseases. These recent developments highlight the dynamic landscape for Century Therapeutics as it advances its cell therapy treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.